For the fifth consecutive year, “Replek” was among the participants and exhibitors at CPHI, one of the world’s leading pharmaceutical trade fairs, which this year was held in Milan from 6 to 8 October, bringing together more than 62,000 participants and 2,900 companies from 166 countries. The company used its participation in CPHI to deepen business cooperation and expand partnerships, as well as to present “Replek’s” potential to partners from various markets, thereby creating new opportunities to increase exports. Expanding its international presence is an integral part of the company’s long-term development strategy.
At this year’s CPHI Milan 2026, the Replek team held meetings with existing and potential partners from various markets, presenting the company’s production capacities, pharmaceutical portfolio and opportunities for cooperation.
“Our fifth participation in CPHI demonstrates that Replek is continuously and strategically building its position in the international pharmaceutical market. For us, CPHI is a platform where we open up new opportunities for cooperation and growth. We have a clear ambition to be present in more markets and, through quality, expertise and continuous investment, to strengthen Replek’s competitiveness and create long-term opportunities for products developed and manufactured in Macedonia,” stated Dushan Pecovski, General Manager of “Replek”.
The continuity of “Replek’s” international presence builds on the company’s recently published sales results for the first nine months of 2026, according to which total sales revenue in the Pharmaceuticals segment reached EUR 21.9 million, with the domestic market and the company’s own representative offices in foreign markets standing out as areas that made a particularly strong contribution to the results.
Namely, during the period January–September 2026, domestic sales reached EUR 7.2 million, representing a 14% increase compared with the same period in 2025. These results confirm the trust that patients, healthcare professionals and business partners place in “Replek’s” products, the positive reception of new products launched during the previous year, as well as the successful implementation of the company’s commercial strategy in the domestic market. At the same time, sales in markets where the company has its own representative offices also recorded growth, reaching EUR 1.3 million, which represents a 56% increase compared with the same period last year. “Replek’s” direct presence through its own representative offices in key foreign markets enables closer monitoring of market needs and more proactive management of commercial activities. Total exports in the first nine months amounted to EUR 14.7 million. The lower export performance compared with the same period last year is related to the postponement of agreed deliveries within part of the partner network, amid changing international market dynamics. In the third quarter, a gradual stabilisation in the pace of export sales was recorded. Contractual obligations remain in force, and the company remains focused on their fulfilment, with cautious expectations regarding the pace of deliveries.
Simultaneously with its market development activities, “Replek” plans to launch four new products by the end of 2026 and continues its investment in the new facility for semi-solid and liquid pharmaceutical dosage forms. The facility is expected to become operational in the second half of 2027, increasing production capacity and creating additional opportunities to expand the company’s portfolio. These investments, together with the development of partnerships and the company’s own representative offices, are aimed at increasing resilience to changes in individual markets, achieving long-term sustainable growth, and creating additional value for its shareholders, employees, partners and patients.